CEMTREX INC (CETX)

US15130G7097 - Common Stock

3.34  +0.17 (+5.36%)

After market: 2.85 -0.49 (-14.67%)

Fundamental Rating

3

Taking everything into account, CETX scores 3 out of 10 in our fundamental rating. CETX was compared to 127 industry peers in the Electronic Equipment, Instruments & Components industry. Both the profitability and financial health of CETX have multiple concerns. CETX is not valued too expensively and it also shows a decent growth rate.



1

1. Profitability

1.1 Basic Checks

In the past year CETX has reported negative net income.
CETX had a negative operating cash flow in the past year.
CETX had negative earnings in each of the past 5 years.
In the past 5 years CETX reported 4 times negative operating cash flow.

1.2 Ratios

The Return On Assets of CETX (-30.03%) is worse than 78.40% of its industry peers.
With a Return On Equity value of -27445.77%, CETX is not doing good in the industry: 98.40% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -30.03%
ROE -27445.77%
ROIC N/A
ROA(3y)-20.93%
ROA(5y)-26.96%
ROE(3y)-83.87%
ROE(5y)-80.93%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of CETX (40.91%) is better than 71.20% of its industry peers.
CETX's Gross Margin has improved in the last couple of years.
CETX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 40.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.26%
GM growth 5Y3.58%

2

2. Health

2.1 Basic Checks

CETX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CETX has less shares outstanding than it did 1 year ago.
CETX has less shares outstanding than it did 5 years ago.
CETX has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -0.91, we must say that CETX is in the distress zone and has some risk of bankruptcy.
CETX has a Altman-Z score of -0.91. This is amonst the worse of the industry: CETX underperforms 81.60% of its industry peers.
A Debt/Equity ratio of 352.23 is on the high side and indicates that CETX has dependencies on debt financing.
CETX has a worse Debt to Equity ratio (352.23) than 98.40% of its industry peers.
Industry RankSector Rank
Debt/Equity 352.23
Debt/FCF N/A
Altman-Z -0.91
ROIC/WACCN/A
WACC4.51%

2.3 Liquidity

CETX has a Current Ratio of 1.89. This is a normal value and indicates that CETX is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.89, CETX is not doing good in the industry: 65.60% of the companies in the same industry are doing better.
A Quick Ratio of 1.35 indicates that CETX should not have too much problems paying its short term obligations.
The Quick ratio of CETX (1.35) is worse than 65.60% of its industry peers.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.35

6

3. Growth

3.1 Past

The earnings per share for CETX have decreased strongly by -597.92% in the last year.
The Revenue has grown by 16.62% in the past year. This is quite good.
Measured over the past years, CETX shows a very strong growth in Revenue. The Revenue has been growing by 21.31% on average per year.
EPS 1Y (TTM)-597.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.77%
Revenue 1Y (TTM)16.62%
Revenue growth 3Y10.92%
Revenue growth 5Y21.31%
Sales Q2Q%-0.27%

3.2 Future

The Earnings Per Share is expected to grow by 26.10% on average over the next years. This is a very strong growth
Based on estimates for the next years, CETX will show a quite strong growth in Revenue. The Revenue will grow by 16.02% on average per year.
EPS Next Y99.69%
EPS Next 2Y41.47%
EPS Next 3Y26.1%
EPS Next 5YN/A
Revenue Next Year18.09%
Revenue Next 2Y16.53%
Revenue Next 3Y16.02%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

4

4. Valuation

4.1 Price/Earnings Ratio

CETX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 5.95 indicates a rather cheap valuation of CETX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CETX indicates a rather cheap valuation: CETX is cheaper than 96.80% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of CETX to the average of the S&P500 Index (22.83), we can say CETX is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 5.95

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

CETX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CETX's earnings are expected to grow with 26.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.47%
EPS Next 3Y26.1%

0

5. Dividend

5.1 Amount

CETX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CEMTREX INC

NASDAQ:CETX (12/20/2024, 8:01:28 PM)

After market: 2.85 -0.49 (-14.67%)

3.34

+0.17 (+5.36%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)12-19 2024-12-19/amc
Earnings (Next)02-10 2025-02-10
Inst Owners48.2%
Inst Owner Change-13.38%
Ins Owners36.54%
Ins Owner Change0%
Market Cap4.48M
Analysts82.86
Price Target11.22 (235.93%)
Short Float %N/A
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1048.46%
Min EPS beat(2)-1944.82%
Max EPS beat(2)-152.1%
EPS beat(4)1
Avg EPS beat(4)-513.29%
Min EPS beat(4)-1944.82%
Max EPS beat(4)74.88%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-6.47%
Min Revenue beat(2)-15.62%
Max Revenue beat(2)2.67%
Revenue beat(4)3
Avg Revenue beat(4)0.55%
Min Revenue beat(4)-15.62%
Max Revenue beat(4)10.36%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.95
P/S 0.07
P/FCF N/A
P/OCF N/A
P/B 93.34
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-125.84
EYN/A
EPS(NY)0.56
Fwd EY16.8%
FCF(TTM)-2.85
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS48.75
BVpS0.04
TBVpS-3.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.03%
ROE -27445.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 40.92%
FCFM N/A
ROA(3y)-20.93%
ROA(5y)-26.96%
ROE(3y)-83.87%
ROE(5y)-80.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.26%
GM growth 5Y3.58%
F-Score3
Asset Turnover1.49
Health
Industry RankSector Rank
Debt/Equity 352.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 183.48%
Cap/Sales 3.72%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.35
Altman-Z -0.91
F-Score3
WACC4.51%
ROIC/WACCN/A
Cap/Depr(3y)149.3%
Cap/Depr(5y)117.4%
Cap/Sales(3y)3.6%
Cap/Sales(5y)3.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-597.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.77%
EPS Next Y99.69%
EPS Next 2Y41.47%
EPS Next 3Y26.1%
EPS Next 5YN/A
Revenue 1Y (TTM)16.62%
Revenue growth 3Y10.92%
Revenue growth 5Y21.31%
Sales Q2Q%-0.27%
Revenue Next Year18.09%
Revenue Next 2Y16.53%
Revenue Next 3Y16.02%
Revenue Next 5YN/A
EBIT growth 1Y1.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y74.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y90.42%
OCF growth 3YN/A
OCF growth 5YN/A